VRTX News

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline.

Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 such patients.

Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions.

VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock faces bearish trend.

Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has risen 18.8% since its last report. The company recently reported that it has 4.01 million shares sold short, which is 1.58% of all regular shares that are available for trading.

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 6.39% on an annualized basis producing an average annual return of 17.51%. Currently, Vertex Pharmaceuticals has a market capitalization of $65.74 billion.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday’s pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to support do